Drugs / Bebtelovimab
Bebtelovimab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04634409 | Oct 2020 → Jul 2021 | COVID-19 | Eli Lilly and Company | Completed | Mixed |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04427501 | Jun 2020 → Feb 2023 | COVID-19 | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT04790786 | Mar 2021 → Jun 2022 | COVID-19 | Erin McCreary | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-02-11 | Eli Lilly and Company | Regulatory Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 lilly.com ↗
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly and Company (NYSE: LLY) announced today. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-06-29 | Eli Lilly and Company | Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options lilly.com ↗ |
| 2022-02-11 | Eli Lilly and Company | Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 lilly.com ↗ |
| 2022-02-10 | Eli Lilly and Company | Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options lilly.com ↗ |
| 2021-05-04 | AbCellera Biologics Inc. | New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials abcellera.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bebtelovimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04634409 ↗ |
| Known as | LY-CoV1404 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802210 ↗ |
| Known as | LY3853113 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04427501 ↗ |
| Modality | Monoclonal antibody | “The monoclonal antibody of bebtelovimab” NCT04790786 ↗ |
| Route | Intravenous | “Administered IV” NCT04427501 ↗ |